news12 July 2020Les Echos : Comment la biotech Da Volterra veut combattre la résistance aux antibiotiquesLa biotech a mis au point un adsorbant intestinal qui capte les résidus d’antibiotiques évitant ainsi la sélection de bactéries…more
news11 June 2020Coronavirus: les autorités sanitaires alertent contre un excès de prescriptions d’antibiotiques, confirmant ainsi le besoin pour des approches préventives telles que DAV132.La Direction générale de la Santé, s’appuyant sur un avis du Haut conseil scientifique, a lancé l’alerte lundi via un…more
news08 June 2020Da Volterra is attending BIO Digital on June 8-12, 2020!The BIO International Convention is the world’s largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings…more
news04 June 2020Da Volterra’s CEO, Florence Séjourné, part of an interactive, virtual panel discussion: “Shifting the Treatment Paradigm: New tools to tackle antimicrobial resistance” during the virtual edition of the 2020 BIO International Convention.Moderator: Natalie Grover, Reporter, Endpoints News. Speakers: Oreola Donini, PhD, Chief Scientific Officer, Soligenix, Inc. Daria Hazuda, VP, Infectious Diseases…more
Non classé26 May 2020New study published in the Journal of Infection Control & Hospital Epidemiology highlights the need for prevention of CDI, especially in patients with hematological malignanciesThe Da Volterra team, along with fellow scientists, is glad to announce the publication of a new study in the…more
news19 May 2020Da Volterra Announces the Publication of Four Abstracts in the 30th ECCMID Abstract BookWe are very happy to share our research with colleagues from around the world in one of the most comprehensive…more
Non classé21 April 2020Da Volterra to present ‘The Perception of Quality of Life Among CDI Patients in the US’ at Peggy Lillis Foundation’ 2020 National C. diff Advocacy Summit on April 21 at 1:10pm ESTLise Lurienne, Market Access Manager at Da Volterra, together with Pierre-Alain Bandinelli, Da Volterra CBO, presented the subject of quality…more
Non classé20 April 2020New article published in the Journal of Hospital Infection highlights the need for prevention of CDI, especially in haematological patients undergoing induction chemotherapy in the USADa Volterra is pleased to present the latest publication of the team on the burden of Clostridioides difficile in patients…more
news09 April 2020A Meta-Analysis of 23 Published Studies Demonstrates the Negative Impact of Antibiotics on the Efficacy of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Patients• The impact of antibiotics on the efficacy of immune checkpoint inhibitors (ICIs) was evaluated in 23 studies including 2,208…more
news11 February 2020Da Volterra Announces Positive Top-line Results from a Phase 2 Clinical Trial Evaluating DAV132 in 260 Patients • First clinical study evaluating DAV132 in patients • Primary endpoint met: DAV132 was safe for use in…more
